Reversal of the International Normalized Ratio with recombinant activated factor VII in central nervous system bleeding during warfarin thromboprophylaxis: clinical and biochemical aspects
暂无分享,去创建一个
[1] J. Ingerslev,et al. Whole blood coagulation thrombelastographic profiles employing minimal tissue factor activation , 2003, Journal of thrombosis and haemostasis : JTH.
[2] S. Kitchen,et al. Rapid reversal of oral anticoagulation with warfarin by a prothrombin complex concentrate (Beriplex): efficacy and safety in 42 patients , 2002, British journal of haematology.
[3] K. Mann,et al. Oral Anticoagulation Thresholds , 2001, Circulation.
[4] H. Roberts. Recombinant factor VIIa (Novoseven) and the safety of treatment. , 2001, Seminars in hematology.
[5] T. Baglin,et al. A comparison of the efficacy and rate of response to oral and intravenous Vitamin K in reversal of over‐anticoagulation with warfarin , 2001, British journal of haematology.
[6] M. Morfini,et al. Use of recombinant factor VIIa (NovoSeven) in patients with Glanzmann thrombasthenia. , 2001, Seminars in hematology.
[7] J. Hirsh,et al. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. , 2001, Chest.
[8] U. Hedner. NovoSeven® as a universal haemostatic agent , 2000, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.
[9] J. Ingerslev,et al. Management and monitoring of recombinant activated factor VII , 2000, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.
[10] P O Byrne,et al. Prothrombin complex concentrate for oral anticoagulant reversal in neurosurgical emergencies. , 2000, British journal of neurosurgery.
[11] E. Berntorp. Recombinant FVIIa in the Treatment of Warfarin Bleeding , 2000, Seminars in thrombosis and hemostasis.
[12] J. Ingerslev. Efficacy and safety of recombinant factor VIIa in the prophylaxis of bleeding in various surgical procedures in hemophilic patients with factor VIII and factor IX inhibitors. , 2000, Seminars in thrombosis and hemostasis.
[13] R. Santoro,et al. Small doses of recombinant factor VIIa in acquired deficiencies of vitamin K dependent factors. , 1999, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.
[14] Gili Kenet,et al. Treatment of traumatic bleeding with recombinant factor VIIa , 1999, The Lancet.
[15] K. Mann,et al. Biochemistry and Physiology of Blood Coagulation , 1999, Thrombosis and Haemostasis.
[16] J. Boissel,et al. The effect of recombinant factor VIIa (NovoSeven™) in healthy volunteers receiving acenocoumarol to an International Normalized Ratio above 2.0 , 1998, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.
[17] M. Peters,et al. Treatment of a Patient with Bernard-Soulier Syndrome and Recurrent Nosebleeds with Recombinant Factor VIIa , 1998, Thrombosis and Haemostasis.
[18] C. van den Bos,et al. Recombinant Factor VIIa in Severe Uremic Bleeding , 1998, Thrombosis and Haemostasis.
[19] J. Boissel,et al. Population Pharmacokinetics of Recombinant Factor VIIa in Volunteers Anticoagulated with Acenocoumarol , 1998, Thrombosis and Haemostasis.
[20] J. Dahlerup,et al. Major haemorrhagic complications during oral anticoagulant therapy in a Danish Population‐based cohort , 1997, Journal of internal medicine.
[21] J. Oliver,et al. Platelet activity of high‐dose factor VIIa is independent of tissue factor , 1997, British journal of haematology.
[22] F. Rosendaal,et al. Emergency Oral Anticoagulant Reversal: The Relative Efficacy of Infusions of Fresh Frozen Plasma and Clotting Factor Concentrate on Correction of the Coagulopathy , 1997, Thrombosis and Haemostasis.
[23] T. Ortel,et al. Plasma levels of factors II, VII and X and their relationship to the international normalized ratio during chronic Warfarin therapy , 1997, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.
[24] L. Tengborn,et al. A Patient with Glanzmann Thrombasthenia and Epistaxis Successfully Treated with Recombinant Factor Vila , 1996, Thrombosis and Haemostasis.
[25] R. White,et al. Temporary Discontinuation of Warfarin Therapy: Changes in the International Normalized Ratio , 1995, Annals of Internal Medicine.
[26] W. T. Sawyer,et al. Pharmacokinetics and pharmacodynamics of recombinant factor VIIa , 1994, Clinical pharmacology and therapeutics.
[27] E. Hylek,et al. Risk Factors for Intracranial Hemorrhage in Outpatients Taking Warfarin , 1994, Annals of Internal Medicine.
[28] J. Vandenbroucke,et al. Bleeding complications in oral anticoagulant therapy : an analysis of risk factors , 1993 .
[29] J. Vandenbroucke,et al. Bleeding complications in oral anticoagulant therapy. An analysis of risk factors. , 1993, Archives of internal medicine.
[30] S. Schulman,et al. Thrombotic Complications after Substitution with a FVII Concentrate , 1991, Thrombosis and Haemostasis.
[31] J. Lusher,et al. Thrombogenicity associated with factor IX complex concentrates. , 1991, Seminars in hematology.
[32] J. Hirsh. Oral anticoagulant drugs. , 1991, The New England journal of medicine.
[33] U. Hedner,et al. Effect of recombinant human FVIIA on warfarin-induced bleeding in rats. , 1990, Thrombosis research.